<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bristol-Myers-Squibb-US1101221083">Bristol-Myers Squibb</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/05/15/bristol-myers-squibb-turns-to-chinas-hengrui-to-replenish-pipeline.html">Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration</a>
    </div>

      <div class="me-0 me-md-5">
        Bristol Myers Squibb this week announced a partnership with Hengrui Pharma to develop drugs together. American and European biopharmaceutical companies are increasingly looking to China for their next blockbusters.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bristol-Myers-Squibb-US1101221083">Bristol-Myers Squibb</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260514235969/en/Tempus-Expands-Strategic-Collaboration-with-Bristol-Myers-Squibb-to-Enhance-the-Probability-of-Success-Across-Clinical-Development-Programs-In-Oncology-and-Neuroscience/">Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience</a>
    </div>

      <div class="me-0 me-md-5">
        CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical &amp; Regulatory Succe...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bristol-Myers-Squibb-US1101221083">Bristol-Myers Squibb</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/12/3293346/0/en/pacira-biosciences-sends-letter-to-stockholders-reiterating-superior-qualifications-of-its-board-nominees.html">Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees</a>
    </div>

      <div class="me-0 me-md-5">
        Highlights Nominees&#39; Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira&#39;s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, n...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bristol-Myers-Squibb-US1101221083">Bristol-Myers Squibb</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/bristol-myers-squibb-and-chinas-hengrui-pharma-forge-tie-up-c6f3ad6e">Bristol-Myers Squibb and China&#39;s Hengrui Pharma Forge Tie-Up</a>
    </div>

      <div class="me-0 me-md-5">
        U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 billion.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bristol-Myers-Squibb-US1101221083">Bristol-Myers Squibb</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/hengrui-pharma-and-bristol-myers-squibb-announce-strategic-agreements-to-advance-innovative-medicines-across-oncology-hematology-and-immunology-302769021.html">Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology</a>
    </div>

      <div class="me-0 me-md-5">
        Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to address significant unmet patient needs and support long ‑ term growth SHANGHAI and PRINCETON, N.J., May 12, 2026 /PRNewswire/ -- Hengrui Pharma (&quot;Hengrui&quot;) (600276.SH; 01276.HK) and Bristol Myers Sq...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bristol-Myers-Squibb-US1101221083">Bristol-Myers Squibb</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/transactional/chinas-jiangsu-hengrui-bristol-myers-squibb-deal-worth-up-152-bln-2026-05-12/">China&#39;s Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln</a>
    </div>

      <div class="me-0 me-md-5">
        China&#39;s Jiangsu ​Hengrui Pharmaceuticals ‌said on Tuesday ​it ​has struck global ⁠strategic collaboration ​and ​licensing deal with U.S. drugmaker ​Bristol ​Myers Squibb to ‌develop ⁠13 early‑stage oncology, hematology ​and ​immunology ⁠programmes, with ​potential ​milestone ⁠payments of up ⁠to $15.2 ​billion.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bristol-Myers-Squibb-US1101221083">Bristol-Myers Squibb</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2026/05/11/is-bristol-myers-squibb-stock-overvalued-at-nearly/">Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.</a>
    </div>

      <div class="me-0 me-md-5">
        Bristol Myers Squibb has faced patent cliffs in recent years and will face more in the next few years. The company&#39;s portfolio of newer drugs, along with its deep pipeline, can help it overcome this headwind.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Bristol-Myers-Squibb-US1101221083">Bristol-Myers Squibb</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">MarketBeat</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketbeat.com/instant-alerts/bristol-myers-squibb-touts-pipeline-gains-as-shareholders-back-board-at-annual-meeting-2026-05-10/?utm_source=snapi">Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        Bristol Myers Squibb NYSE: BMY used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independent board chair.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Bristol-Myers-Squibb-US1101221083/load_more?page=10">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>